Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

telitacicept 2Prednisone 2Blood Specimen Collection 2thymoglobulin 1remdesivir 1prednylidene 1fludarabine 1deltacortene 1carmustine, poliferprosan 20 drug combination 1apremilast 1Vitamin D 1Valsartan 1Telemedicine 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Pyridostigmine Bromide 1Practice Guidelines as Topic 1Population Groups 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Mycophenolic Acid 1Music Therapy 1Methods 1Melphalan 1Mastectomy, Segmental 1Mammaplasty 1Interviews as Topic 1Infliximab 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Autoimmune Diseases × Nivolumab × Clear all
NCT03656627 2023-02-15

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Alliance Foundation Trials, LLC.

Phase 1 Terminated
7 enrolled
Thoracic

Arthritis, Rheumatoid, Autoimmune Diseases, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Crohn Disease, Lupus Erythematosus, Systemic, Multiple Sclerosis, Polymyalgia Rheumatica, Psoriasis, Giant Cell Arteritis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡